Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsNSE:APLLTD +0.01%87 EV-to-EBITDA is 15.07 as of Aug. 15, 2026, which is 4% below its 10-year median of 15.67. GuruFocus rates NSE:APLLTD with a GF Score™ of 87/100 and a GF Value™ of ₹1,099.66 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 735 Drug Manufacturers companies, Alembic Pharmaceuticals ranks worse than 54.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alembic Pharmaceuticals's enterprise value is ₹175,661 Mil.
Alembic Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹11,659 Mil. Therefore, Alembic Pharmaceuticals's EV-to-EBITDA for today is 15.07.
The historical rank and industry rank for Alembic Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:APLLTD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.67 Med: 15.67 Max: 24.78
Current: 15.07
During the past 13 years, the highest EV-to-EBITDA of Alembic Pharmaceuticals was 24.78. The lowest was 9.67. And the median was 15.67.
NSE:APLLTD's EV-to-EBITDA is ranked worse than 54.97% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs NSE:APLLTD: 15.07
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alembic Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Alembic Pharmaceuticals's share price for today is ₹831.25.
Alembic Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's EV-to-EBITDA falls into.
Alembic Pharmaceuticals's current Enterprise Value is ₹175,661 Mil.
Alembic Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11,659 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals (NSE:APLLTD) has a EV-to-EBITDA of 15.07 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alembic Pharmaceuticals. This is near median its historical median of 15.67. Over the past decade, Alembic Pharmaceuticals' EV-to-EBITDA has ranged from 9.67 to 24.78. According to the industry distribution chart, Alembic Pharmaceuticals ranks #404 out of 735 companies in the Drug Manufacturers industry, placing it in the top 55%.
Is Alembic Pharmaceuticals' EV-to-EBITDA too high?
Alembic Pharmaceuticals' current EV-to-EBITDA of 15.07 is near median its 10-year median of 15.67. Over the past 10 years, this metric has ranged from a low of 9.67 to a high of 24.78. The Drug Manufacturers industry median EV-to-EBITDA is 13.30. Alembic Pharmaceuticals' value of 15.07 is 13.3% above this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #404 out of 735 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alembic Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #404 out of 735 companies for EV-to-EBITDA. This places Alembic Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. Alembic Pharmaceuticals' value of 15.07 is 13.3% above this benchmark. Historically, Alembic Pharmaceuticals' own EV-to-EBITDA has ranged from 9.67 to 24.78 over the past decade. While the company's 10-year median is 15.67 vs. the industry median of 13.30, Alembic Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current EV-to-EBITDA of 15.07 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alembic Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current EV-to-EBITDA is 15.07, which is near median its own 10-year median of 15.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (NSE:APLLTD) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,099.66, compared to a current price of ₹831.25 — trading 24.4% below its estimated fair value. The current EV-to-EBITDA is 15.07, which is near median its 10-year median of 15.67 and 13.3% above the Drug Manufacturers industry median of 13.30. Alembic Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alembic Pharmaceuticals (NSE:APLLTD), the current EV-to-EBITDA is 15.07 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (NSE:APLLTD) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹831.25 is trading 24.4% below its estimated GF Value™ of ₹1,099.66.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:APLLTD:
EV-to-EBITDA: 15.07 (near median its 10-year median of 15.67)
GF Value™: ₹1,099.66 vs. price of ₹831.25 (24.4% below fair value)
Industry Position: 13.3% above the Drug Manufacturers median (#404 of 735)
No single metric tells the full story. See the NSE:APLLTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
87GF Score
Get the complete analysis for NSE:APLLTD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APLLTD has been successfully added to your 
